RxDoctor Payments Data

Geoffrey Rosevear

Family · Johnson City, NYNPI 1225364854

Payments from drug & device makers

$4,560in general payments, 2019–2025

Across 232 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$819
  • Johnson & Johnson$618
  • Pfizer$517
  • Amgen$436
  • Merck$384
  • E.r. Squibb & Sons, L.L.C.$291
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$4,546100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,560 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.

See all family providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban193$261,845
EntrestoSacubitril/Valsartan135$208,108
FarxigaDapagliflozin Propanediol102$90,517
XareltoRivaroxaban64$80,142
TrulicityDulaglutide49$41,723
JardianceEmpagliflozin31$38,644
BrilintaTicagrelor41$33,215
Repatha SureclickEvolocumab19$17,982
Lacosamide25$9,329
Metoprolol Succinate379$8,447
MyrbetriqMirabegron34$7,837
Incruse ElliptaUmeclidinium Bromide18$6,797
Asenapine Maleate13$6,404
Atorvastatin Calcium359$4,707
Ranolazine ErRanolazine38$4,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$517$261,845193 claims
NovartisEntresto$819$208,108135 claims
AstraZenecaFarxiga, Brilinta$185$123,732143 claims
Johnson & JohnsonXarelto$618$80,14264 claims
Boehringer IngelheimJardiance$237$38,64431 claims
GSKIncruse Ellipta$85$6,79718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.

Other family in Johnson City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →